For many patients with lower-risk localized prostate cancer, forgoing or delaying definitive therapy through active surveillance (AS) can help them avoid significant side effects associated with surgery or radiation.
Related Articles
ArteraAI’s Commitment to HIPAA
With ArteraAI’s expansion, we understand that security is a necessity. So we are pleased to announce that ArteraAI is HIPAA c [...]
ArteraAI Achieves SOC 2 Type II Security Compliance Certification
ArteraAI x SOC 2 As part of our commitment to cybersecurity, we are proud to announce that ArteraAI is now SOC 2 Type II cert [...]